News articles about Exelixis (NASDAQ:EXEL) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Exelixis earned a news impact score of 0.22 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 86 out of 100, meaning that recent press coverage is very likely to have an impact on the stock’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- EXELIXIS INC. DL-01 (EX9.DE) Sees The Tape Move Mid-Market – Evergreen Caller (evergreencaller.com)
- Exelixis, Inc. Continued Its Winning Ways and Rose 10% in July Thanks to These 3 Catalysts – Motley Fool (fool.com)
- (EXEL) Rating Reiterated by Piper Jaffray Companies (wisdomsave.com)
- Q3 2017 EPS Estimates for Exelixis, Inc. Lifted by William Blair (EXEL) (vothemes.com)
Several research analysts have recently commented on EXEL shares. William Blair reaffirmed an “outperform” rating on shares of Exelixis in a report on Friday, June 16th. Oppenheimer Holdings, Inc. started coverage on shares of Exelixis in a report on Monday, June 12th. They issued a “hold” rating for the company. Zacks Investment Research raised shares of Exelixis from a “hold” rating to a “strong-buy” rating and set a $28.00 price target for the company in a report on Tuesday, July 4th. Cann reaffirmed a “hold” rating on shares of Exelixis in a report on Thursday, July 20th. Finally, BidaskClub raised shares of Exelixis from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Five analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Exelixis has a consensus rating of “Buy” and a consensus price target of $25.57.
Exelixis (EXEL) traded down 0.04% during mid-day trading on Wednesday, hitting $27.19. 3,418,375 shares of the company’s stock were exchanged. The stock has a market capitalization of $7.99 billion, a P/E ratio of 141.61 and a beta of 1.89. The firm has a 50 day moving average of $25.47 and a 200 day moving average of $21.97. Exelixis has a 52 week low of $10.04 and a 52 week high of $28.45.
Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. Exelixis had a net margin of 18.20% and a return on equity of 80.43%. The firm had revenue of $99.01 million for the quarter, compared to analyst estimates of $85.27 million. During the same quarter in the prior year, the firm earned ($0.15) EPS. The company’s revenue was up 173.1% on a year-over-year basis. Equities analysts forecast that Exelixis will post $0.25 earnings per share for the current fiscal year.
In other Exelixis news, Director Carl B. Feldbaum sold 32,988 shares of the company’s stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $21.58, for a total transaction of $711,881.04. Following the transaction, the director now directly owns 52,721 shares in the company, valued at approximately $1,137,719.18. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Patrick J. Haley sold 5,000 shares of the company’s stock in a transaction dated Tuesday, May 30th. The shares were sold at an average price of $18.46, for a total transaction of $92,300.00. The disclosure for this sale can be found here. Corporate insiders own 5.10% of the company’s stock.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.